HLS Therapeutics (TSX:HLS) EPS (Basic) : C$-1.15 (TTM As of Mar. 2024)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics EPS (Basic)?

HLS Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was C$-0.26. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.15.

HLS Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was C$-0.26. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-1.15.

HLS Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was C$-0.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -0.91.

During the past 3 years, the average EPS without NRI Growth Rate was -5.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, HLS Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 93.00% per year. The lowest was -105.90% per year. And the median was -2.60% per year.

HLS Therapeutics EPS (Basic) Historical Data

The historical data trend for HLS Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics EPS (Basic) Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.88

-0.62

-0.53

-0.99

-1.14

HLS Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial															-0.25	-0.39	-0.28	-0.23	-0.26

HLS Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

HLS Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-36.936	-	0)	/	32.263
	=	-1.14

HLS Therapeutics's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.265	-	0)	/	31.940
	=	-0.26

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.15

HLS Therapeutics (TSX:HLS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

HLS Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (TSX:HLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

Executives

Polar Asset Management Partners Inc.

10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines